135 related articles for article (PubMed ID: 34583744)
1. PRO B: evaluating the effect of an alarm-based patient-reported outcome monitoring compared with usual care in metastatic breast cancer patients-study protocol for a randomised controlled trial.
Karsten MM; Kühn F; Pross T; Blohmer JU; Hage AM; Fischer F; Rose M; Grittner U; Gebert P; Ferencz J; Pauler L; Breidenbach C; Kowalski C;
Trials; 2021 Sep; 22(1):666. PubMed ID: 34583744
[TBL] [Abstract][Full Text] [Related]
2. Statistical analysis plan for the PRO B study: open-label, superiority randomised controlled trial of alarm-based patient-reported outcome monitoring in patients with metastatic breast cancer.
Gebert P; Karsten MM; Hage AM; Dordevic AD; Grittner U
Trials; 2024 Mar; 25(1):171. PubMed ID: 38448904
[TBL] [Abstract][Full Text] [Related]
3. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
4. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
[TBL] [Abstract][Full Text] [Related]
5. Application of the patient-reported outcome-based postoperative symptom management model in lung cancer: a multicenter randomized controlled trial protocol.
Liang Y; Jing P; Gu Z; Shang L; Ge P; Zhang Y; Wang L; Qiu C; Zhu X; Tan Z
Trials; 2024 Feb; 25(1):130. PubMed ID: 38365704
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
10. A complex nursing intervention of complementary and alternative medicine (CAM) to increase quality of life in patients with breast and gynecologic cancer undergoing chemotherapy: study protocol for a partially randomized patient preference trial.
Klafke N; Mahler C; von Hagens C; Rochon J; Schneeweiss A; Müller A; Salize HJ; Joos S
Trials; 2015 Feb; 16():51. PubMed ID: 25887713
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
[TBL] [Abstract][Full Text] [Related]
12. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
Velikova G; Williams LJ; Willis S; Dixon JM; Loncaster J; Hatton M; Clarke J; Kunkler IH; Russell NS;
Lancet Oncol; 2018 Nov; 19(11):1516-1529. PubMed ID: 30337220
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
[TBL] [Abstract][Full Text] [Related]
14. PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.
Mollerup A; Larsen SC; Bennetzen AS; Henriksen M; Simonsen MK; Weis N; Kofod LM; Heitmann BL
BMJ Open; 2021 Jun; 11(6):e050582. PubMed ID: 34193503
[TBL] [Abstract][Full Text] [Related]
15. TANGO: effect of tango Argentino on cancer-associated fatigue in breast cancer patients-study protocol for a randomized controlled trial.
Oei SL; Rieser T; Becker S; Groß J; Matthes H; Schad F; Thronicke A
Trials; 2021 Dec; 22(1):866. PubMed ID: 34857031
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of a digital health intervention with proactive follow-up by nurses to improve healthcare and outcomes for patients with breast cancer in Mexico: protocol for a randomised clinical trial.
Contreras Sánchez SE; Doubova SV; Grajales Álvarez R; Dip Borunda AK; Martínez Pineda WJ; Nuñez Cerrillo JG; Silva Bravo F; Zalapa Velázquez R; Gutiérrez De la Barrera M; Leslie HH
BMJ Open; 2023 Nov; 13(11):e077322. PubMed ID: 37931967
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial.
Atreja A; Khan S; Rogers JD; Otobo E; Patel NP; Ullman T; Colombel JF; Moore S; Sands BE;
JMIR Res Protoc; 2015 Feb; 4(1):e23. PubMed ID: 25693610
[TBL] [Abstract][Full Text] [Related]
19. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care).
Osawa T; Fujii Y; Kimura G; Kitamura H; Nagashima Y; Iizumi S; Osaka T; Tsubouchi R; Shinohara N
BMJ Open; 2023 Jul; 13(7):e070275. PubMed ID: 37495393
[TBL] [Abstract][Full Text] [Related]
20. Study protocol of the TIRED study: a randomised controlled trial comparing either graded exercise therapy for severe fatigue or cognitive behaviour therapy with usual care in patients with incurable cancer.
Poort H; Verhagen CA; Peters ME; Goedendorp MM; Donders AR; Hopman MT; Nijhuis-van der Sanden MW; Berends T; Bleijenberg G; Knoop H
BMC Cancer; 2017 Jan; 17(1):81. PubMed ID: 28129746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
